Veru Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 0.65
Dividend & YieldN/A$ (N/A)
Beta -0.2
Market capitalization 442.41M
Operating cash flow -27.43M
ESG Scores unknown

Company description

Veru Inc., a biopharmaceutical company, focuses on developing medicines for the management of breast and prostate cancers. Its commercial products comprise FC2 female condom/internal condom for the protection against unintended pregnancy and the transmission of sexually transmitted infections; and Entadfi, a capsule for the treatment of urinary tract symptoms. The company's drug candidates under development include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase 2b clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral cytoskeleton disruptor plus selective androgen receptor agonist that is in phase 2b clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase 3 clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase 2b clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

Sector: Healthcare - Industry: Biotechnology

Financial Ratios
Quick Ratio9.27
Working Capital0.05
Return On Equity0.05
Debt To Equity0.06
Fixed Asset Ratio0.02
Fixed Interest Cover-1.11

Financial data

Financial Statements

Cashflow Statement 2018-09-30 2019-09-30 2020-09-30 2021-09-30
Change To Liabilities 8.9k -56.94k -312.08k 597.1k
Total Cashflows From Investing Activities -50.65k -108.52k -105.76k 14.62M
Net Borrowings 9.36M -4.94M -4.44M -19.43k
Total Cash From Financing Activities 12.08M 8.13M 9.33M 109.72M
Change To Operating Activities 1.28M 1.3M -644.86k -4.86M
Issuance Of Stock 3.07M 13.33M 13.82M 109.88M
Net Income -23.94M -12.02M -18.97M 7.39M
Change In Cash 481.91k 2.54M 7.29M 108.77M
Effect Of Exchange Rate
Total Cash From Operating Activities -11.55M -5.49M -1.93M -15.57M
Depreciation 452.05k 471.42k 462.74k 211.39k
Change To Account Receivables 1.87M -1.35M -87.79k -3.56M
Other Cashflows From Financing Activities -344.76k -268.03k -50.28k -137.69k
Change To Netincome 8.4M 7.62M 20.93M -15.89M
Capital Expenditures -50.65k -108.52k -105.76k -376.65k

Income Statement 2018-09-30 2019-09-30 2020-09-30 2021-09-30
Research Development 10.85M 13.74M 17.06M 32.69M
Income Before Tax -23.07M -12.32M -20.05M 4.27M
Net Income -23.94M -12.02M -18.97M 7.39M
Selling General Administrative 14.81M 14.35M 14.92M 20.67M
Gross Profit 8.77M 21.66M 30.79M 47.93M
Ebit -16.89M -6.44M -1.19M -5.44M
Operating Income -16.89M -6.44M -1.19M -5.44M
Interest Expense -2.95M -4.71M -4.62M -4.89M
Income Tax Expense 866.1k -303.93k -1.08M -3.13M
Total Revenue 15.86M 31.8M 42.59M 61.26M
Cost Of Revenue 7.09M 10.15M 11.81M 13.33M
Total Other Income ExpenseNet -6.19M -5.89M -18.87M 9.7M
Net Income From Continuing Ops -23.94M -12.02M -18.97M 7.39M
Net Income Applicable To Common Shares -23.94M -12.02M -18.97M 7.39M

Balance Sheet Statement 2018-09-30 2019-09-30 2020-09-30 2021-09-30
Total Liabilities 18.97M 21.3M 21.43M 25.85M
Total Stockholder Equity 29.48M 32.33M 30.11M 152.29M
Other Current Liabilities 191.16k 249k 6k 132k
Total Assets 48.45M 53.63M 51.54M 178.15M
Common Stock 574.69k 672.22k 720.47k 821.53k
Other Current Assets 613.27k 9.17M
Retained Earnings -58.2M -70.22M -89.19M -81.8M
Treasury Stock -8.39M -8.39M -8.39M -8.39M
Cash 3.76M 6.3M 13.59M 122.36M
Total Current Liabilities 13.55M 14.02M 14.73M 15.77M
Other Stockholder Equity -581.52k -581.52k -581.52k -581.52k
Property, Plant, and Equipment 404.55k 351.89k 1.67M 1.56M
Total Current Assets 11.18M 16.81M 27.01M 151.75M
Net Tangible Assets 2.12M 5.29M 17.48M 141.37M
Net Receivables 3.97M 5.02M 5.23M 13.79M
Accounts Payable 3.23M 3.12M 2.81M 3.41M


Insider Transactions

Here are the insider transactions of stock shares related to Veru Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
EISENBERGER MARIOSale at price 20.04 per share.D2022-08-15Director100k
EISENBERGER MARIOConversion of Exercise of derivative security at price 1.20 - 2.08 per share.D2022-08-15Director100k
LU LUCYPurchase at price 6.78 per share.D2021-08-17Director4.8k
FISCH HARRYSale at price 8.35 per share.D2021-06-16Director and Beneficial Owner of more than 10% of a Class of Security100k
HYUN GRACEPurchase at price 14.09 per share.D2021-03-10Director3.5k
STEINER MITCHELL SHUSTERSale at price 20.88 per share.I2021-02-12Chief Executive Officer20k
STEINER MITCHELL SHUSTERSale at price 9.69 per share.D2020-12-16Chief Executive Officer250k
BARNETTE K GARY PH.D.Sale at price 10.65 per share.D2020-12-16Officer100k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Veru Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Veru Inc

Here is the result of two systematic investment strategies applied to Veru Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Veru Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Veru Inc:

Veru Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 256.38% on the backtest period.

Performance at glance

Performance

256.38 %

Latent gain

5768.05 $

Invested capital

2249.83 $

Annualized return

61.93 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Veru Inc

This is the result of two momentum investment strategies applied to Veru Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Veru Inc

The following chart shows all the entries opened by the momentum investment system on Veru Inc:

Veru Inc momentum entries
  • The first momentum investment strategy would give 348.11% of return on Veru Inc. That represents 15656.08$ of latent gain with 4497.46$ of employed capital.
  • The second momentum investment strategy would give 381.74% of return on Veru Inc. That represents 9530.27$ of latent gain with 2496.55$ of employed capital.
Performance at glance (1Q Momentum)

Performance

348.11 %

Latent gain

15656.08 $

Invested capital

4497.46 $

Annualized return

0.0 %
Performance at glance (2Q Momentum)

Performance

381.74 %

Latent gain

9530.27 $

Invested capital

2496.55 $

Annualized return

104.3 %

Momentum equity curve on Veru Inc

The following chart shows the equity curve of the two momentum strategies applied to Veru Inc:

Veru Inc momentum equity

Note: the dividends potentially given by Veru Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Veru Inc

The following chart shows the employed capital evolution of the two momentum strategies on Veru Inc since the beginning:

Veru Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Veru Inc

Buy the dip entry openings on Veru Inc

Veru Inc

The performance achieved by the robo-advisor on Veru Inc is 0%. That represents 0.0$ of latent gain with 0.0$ of employed capital. The following chart shows Veru Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Veru Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 $

Invested capital

0.0 $

Annualized return

0.0 %

Equity curve of the strategy applied to Veru Inc

The following chart shows the result of the investment strategy applied to Veru Inc:

Veru Inc

Note: the dividends potentially given by Veru Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Veru Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Veru Inc:

Veru Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Veru Inc

In this section, I will compare the three previous investment strategies applied to Veru Inc.

Equity curve comparison on Veru Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Veru Inc investment strategy comparison

Employed capital comparison on Veru Inc

Veru Inc investment comparison

Performance comparison on Veru Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 256.38% 5768.05$ 2249.83$ 61.93%
Momentum 1 quarter 348.11% 15656.08$ 4497.46$ 89.26%
Momentum 2 quarters 381.74% 9530.27$ 2496.55$ 104.3%
Non-directional 0% 0.0$ 0.0$ 0.0%
Annualized return comparison

Automatic investment

61.93 %

Momentum 1Q

104.3 %

Momentum 2Q

104.3 %

Non-directional

0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Veru Inc:

Positive correlations

Most correlated stocks this year

  • Veru Inc

  • Most correlated stocks last 3 months

  • AVEO Pharmaceuticals Inc
  • Veru Inc
  • TRAINLINE PLC ORD 1P

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months

  • INTEGRAGEN

  • Note: The algorithm computes the probability of correlation between Veru Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Veru Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Veru Inc
    Country United States
    City Miami
    Address 2916 North Miami Avenue
    Phone 305 509 6897
    Website www.verupharma.com
    FullTime employees 252
    Industry Biotechnology
    Sector Healthcare
    Exchange XNAS
    Ticker VERU
    Market www.nasdaq.com

    Veru Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown